Bellevue Group’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-278,286
Closed -$3.27M 181
2025
Q4
$3.27M Sell
278,286
-91,912
-25% -$992K 0.06% 83
2025
Q3
$2.86M Sell
370,198
-542,884
-59% -$3.8M 0.06% 89
2025
Q2
$6.67M Sell
913,082
-303,674
-25% -$2.45M 0.15% 76
2025
Q1
$11.5M Buy
1,216,756
+160,960
+15% +$2.01M 0.26% 69
2024
Q4
$17.4M Sell
1,055,796
-556,816
-35% -$8.65M 0.33% 70
2024
Q3
$23.8M Buy
1,612,612
+410,516
+34% +$6.42M 0.39% 67
2024
Q2
$16.7M Buy
1,202,096
+256,071
+27% +$3.63M 0.27% 82
2024
Q1
$14.9M Buy
+946,025
New +$14.6M 0.23% 87
2022
Q1
Sell
-469,695
Closed -$16M 194
2021
Q4
$16M Sell
469,695
-91,988
-16% -$3.6M 0.17% 105
2021
Q3
$27.1M Sell
561,683
-256,630
-31% -$11.9M 0.28% 95
2021
Q2
$37M Buy
818,313
+30,360
+4% +$1.35M 0.36% 85
2021
Q1
$38M Buy
787,953
+239,507
+44% +$12.5M 0.4% 82
2020
Q4
$29.5M Buy
548,446
+121,554
+28% +$5.49M 0.34% 80
2020
Q3
$15.7M Sell
426,892
-58,578
-12% -$2.18M 0.22% 97
2020
Q2
$15M Buy
+485,470
New +$13.5M 0.21% 90

Other funds holding NEO

Bellevue Group's NEO Position: Q1 2026 in Review

Bellevue Group sold out of NeoGenomics (NEO) in Q1 2026, closing a stake of 278,286 shares — an estimated $3.27M sold.

Bellevue Group first reported a position in NEO in Q2 2020 and held it in 15 quarters. The position peaked at $38M in Q1 2021. 253 funds tracked by Wall St. Rank hold NEO as of Q1 2026.

  • Bellevue Group reported no remaining NeoGenomics position as of Q1 2026 after selling out during the quarter.
  • Bellevue Group sold 278,286 NeoGenomics shares in Q1 2026, an estimated $3.27M.
  • Bellevue Group first reported a position in NeoGenomics in Q2 2020 and held it in 15 quarters.
  • Bellevue Group's NeoGenomics position peaked at $38M in Q1 2021.
  • 253 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.